Aldactone-Spironolactone is the oral diuretic medication designed for use in treating the congestive heart failure and blood pressure disorders and has been officially approved by the Food and Drugs Administration-FDA of the United States. The drug also tends to block testosterone aiding to avert hair loss while promoting the re-growth of hair. This drug is also used to help enhance the amount of potassium in the body when it is observed getting excessively lower. The drug has been formulated in the tablet form by the world renowned pharmaceutical giants Pfizer Incorporated of the United States of America.

Aldactone-Spironolactone is the typical pharmacological antagonist of aldosterone which basically functions through competitive binding receptors as the aldosterone dependent, sodium potassium exchange site in the distal complex renal tubule. The drug causes improved quantity of sodium and water to be emitted while maintaining minimal loss of potassium in the body. This medication is found to be acting both as the diuretic agent as well as the anti-hypertensive drug due to such mechanism. The medication may be given singly or with other diuretic agents that function rather proximally in the renal tubule.

The drug is said to enhance levels of mineralocorticoid, aldosterone that are present in the primary and secondary hyperaldosteronism. An edematous phase wherein secondary aldosteronism is normally absorbed incorporates congestive heart failure, hepatic cirrhosis and nephritic syndrome. The action of antagonizing the effect of aldosterone, this drug inhibits the exchange of sodium for potassium in the distal renal tubule and helps preventing potassium loss. Aldactone-Spironolactone has not been demonstrated of raising serum uric acid to impulsive gout or to change carbohydrate metabolism.